TY - JOUR
T1 - Structure basis of CFTR folding, function and pharmacology
AU - Hwang, Tzyh-Chang
AU - Braakman, Ineke
AU - van der Sluijs, Peter
AU - Callebaut, Isabelle
N1 - Funding Information:
The authors acknowledge funding from i) NIH (NIHR01:DK55835); the Cystic Fibrosis Foundation (grant Hwang19G0), Ministry of Science and Technology, Taiwan (109–2320-B-010–049-MY2), and Veterans General Hospitals and University System of Taiwan Joint Research Program, Taiwan (VGHUST111-G6–10–1) (to TCH), ii) Cystic Fibrosis Foundation (CFF; BRAAKM14XX0, BRAAKM18G0), the Dutch Research Council (NWO; 731.016.403), the Netherlands Cystic Fibrosis Foundation (HIT-CF 2.0), and Stichting Zeldzame Ziekte Fonds via Stichting Muco & Friends (to IB/PvdS), iii) the French association Vaincre La Mucoviscidose (to IC).
Funding Information:
The authors acknowledge funding from i) NIH (NIHR01:DK55835); the Cystic Fibrosis Foundation (grant Hwang19G0), Ministry of Science and Technology, Taiwan (109–2320-B-010–049-MY2), and Veterans General Hospitals and University System of Taiwan Joint Research Program, Taiwan (VGHUST111-G6–10–1) (to TCH), ii) Cystic Fibrosis Foundation (CFF; BRAAKM14XX0, BRAAKM18G0), the Dutch Research Council (NWO; 731.016.403), the Netherlands Cystic Fibrosis Foundation (HIT-CF 2.0), and Stichting Zeldzame Ziekte Fonds via Stichting Muco & Friends (to IB/PvdS), iii) the French association Vaincre La Mucoviscidose (to IC). This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS).
Publisher Copyright:
© 2022
PY - 2023/3
Y1 - 2023/3
N2 - The root cause of cystic fibrosis (CF), the most common life-shortening genetic disease in the Caucasian population, is the loss of function of the CFTR protein, which serves as a phosphorylation-activated, ATP-gated anion channel in numerous epithelia-lining tissues. In the past decade, high-throughput drug screening has made a significant stride in developing highly effective CFTR modulators for the treatment of CF. Meanwhile, structural-biology studies have succeeded in solving the high-resolution three-dimensional (3D) structure of CFTR in different conformations. Here, we provide a brief overview of some striking features of CFTR folding, function and pharmacology, in light of its specific structural features within the ABC-transporter superfamily. A particular focus is given to CFTR's first nucleotide-binding domain (NBD1), because folding of NBD1 constitutes a bottleneck in the CFTR protein biogenesis pathway, and ATP binding to this domain plays a unique role in the functional stability of CFTR. Unraveling the molecular basis of CFTR folding, function, and pharmacology would inspire the development of next-generation mutation-specific CFTR modulators.
AB - The root cause of cystic fibrosis (CF), the most common life-shortening genetic disease in the Caucasian population, is the loss of function of the CFTR protein, which serves as a phosphorylation-activated, ATP-gated anion channel in numerous epithelia-lining tissues. In the past decade, high-throughput drug screening has made a significant stride in developing highly effective CFTR modulators for the treatment of CF. Meanwhile, structural-biology studies have succeeded in solving the high-resolution three-dimensional (3D) structure of CFTR in different conformations. Here, we provide a brief overview of some striking features of CFTR folding, function and pharmacology, in light of its specific structural features within the ABC-transporter superfamily. A particular focus is given to CFTR's first nucleotide-binding domain (NBD1), because folding of NBD1 constitutes a bottleneck in the CFTR protein biogenesis pathway, and ATP binding to this domain plays a unique role in the functional stability of CFTR. Unraveling the molecular basis of CFTR folding, function, and pharmacology would inspire the development of next-generation mutation-specific CFTR modulators.
KW - ABC transporter
KW - CFTR
KW - corrector
KW - modulator
KW - potentiator
UR - http://www.scopus.com/inward/record.url?scp=85139710599&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2022.09.010
DO - 10.1016/j.jcf.2022.09.010
M3 - Article
C2 - 36216744
SN - 1569-1993
VL - 22
SP - S5-S11
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - S1
ER -